Episode Details

Mesoblast (MESO) FY2026 — FY2026 (twelve months ended June 30, 2026): total revenue $120.25m vs $17.2m, up 599.2%; net Ryoncil product sales $115.2m vs $11.3m; gross profit ex-amortisation $109.7m, a 91.2% margin; R&D $97.5m vs $34.8m; SG&A $57.3m vs $39.3m; reported loss $57.5m vs $102.1m; loss per ADS $0.444. The ADS closed $18.18 on August 27, up 7.96% on 541,633 shares, 3.0x its 30-session median. Mesoblast filed its audited 20-F at 06:08 Eastern on August 27 and the results 6-K at 07:09, both before the open, and the stock closed up 7.96% on three times median volume. The launch is real: Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, did $115.2m of net product sales in its first full year, the second half out-earned the first by 34.2%, and the fourth quarter alone did $36m. The release leads with a loss cut 44% to $57.5m. But $32.8m of that $44.6m improvement - 73.4% - is the swing in two non-cash fair value lines. Strip them and $103.1m of new revenue bought $11.9m of loss reduction. THE CALL: BEARISH (3/5, A GENUINELY GOOD FIRST LAUNCH YEAR THAT IS NOT WHAT THE SHARE PRICE IS PAYING FOR) — base-case value ~$14.28 vs ~$18.18 today. KEY METRICS: - THE SPINE: the reported loss narrowed $44.6m, but $32.8m of that - 73.4% - is two non-cash fair value marks, not the business. - EX-MARKS: the underlying loss went $82.3m to $70.4m. So $103.1m of new revenue bought $11.9m of improvement - 11.5% drop-through. - THE MARKS: contingent consideration swung from a $14.9m charge to a $12.1m gain; the warrant liability from a $5.0m charge to a gain. - THE CASH: $88.4m received against $120.25m booked. Receivables $14.9m to $57.7m, 175 days, and one customer is the entire product book. - THE BALANCE SHEET: intangibles $566.4m are 99.6% of $568.4m net assets. Borrowings $119.2m vs $102.9m cash - net debt, in year one. - THE CONCESSION: second-half revenue $68.9m vs $51.3m, +34.2%. Q4 product sales $36m annualise to $144m. 50 centres, 280m covered lives. - WHAT YOU PAY FOR: our approved franchise is $9.87 an ADS. The tape is $18.18, so $8.31 - 46% - is six unapproved programmes. - OUR CALL: BEARISH, 3/5, fair value $14.28 vs $18.18. Bear $7.28, base $14.16, bull $21.51. Two April targets, both $35.00. What to watch: UP: revenue $120.25m beat the $117.5m seven-analyst consensus by 2.3%; second-half revenue $68.9m against a $51.3m first half; Q4 product sales $36m annualise to $144m; operating cash outflow only $13.4m in the second half; gross-to-net 13.4% against 14.6%; 50+ transplant centres including 14 of the 15 largest; 280m covered lives; time to treatment 29 days to 8. DOWN: cash receipts $88.4m against $120.25m of revenue; receivables $14.9m to $57.7m, 175 days, and the 20-F says one single external customer is the whole product book; intangibles $566.4m are 99.6% of net assets; borrowings $119.2m against $102.9m of cash is net debt; finance costs $23.8m are 19.8% of revenue. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.